Join Us in Making a Difference

Welcome to the Medicines Patent Pool (MPP) support page. We are a Geneva-based public health organisation dedicated to expanding access to essential medicines and health technologies in lowand middle-income countries (LMICs). Your support is crucial in helping us achieve our mission of ensuring that life-saving scientific advancements reach those who need them most.

Learn more about usOur business model

Why Support MPP?

MPP’s innovative model pushes the boundaries so that everyone,
regardless of where they live, has the power to achieve a healthy future.

Expanding Access, Saving Lives: Join MPP's Mission

In this video, Charles Gore, Executive Director of MPP, calls for support to further scale
MPPs impact and ensure equitable global health.

Urgent Health Challenges

Millions in low- and middle-income countries face urgent health challenges. Nearly 2 billion people lack access to the medicines they need, undermining individual well-being, health system resilience, and global health security.

Sustainable Solutions

Unlike other NGOs, MPP provides sustainable solutions that save millions of lives in the short and long run.
MPP is very small for what it achieves, saving the global health community billions of dollars.

Proven Impact

Since our founding by Unitaid in 2010, MPP has delivered over 43 billion treatment doses in 148 countries, saving the global health community USD 1.9 billion. Today, 24 million people living with HIV in low- and middle-income countries have access to affordable quality generic medicines thanks to an MPP licence negotiated in 2014 for the WHO-recommended treatment of dolutegravir.

Mission

Our mission is to increase equitable access to innovative medicines and other health technologies through public health-oriented voluntary licensing and technology transfer.

Vision

A world in which people in need in low- and middle-income countries (LMICs) have rapid access to effective and affordable medical treatments and health technologies.

Voluntary Licensing

MPP negotiates voluntary licences with pharmaceutical companies, enabling the production of affordable, quality-assured generic
medicines. This model creates a win-win situation: originator companies retain control and recognition for their innovations, while generic
manufacturers supply affordable versions, resulting in faster, more equitable access to treatment.

Collaborative Solutions

By sublicensing intellectual property to multiple manufacturers, MPP fosters healthy competition that drives down prices
and expands supply. Our approach strengthens the IP system by making it work better for public health, ensuring that
scientific breakthroughs reach the people who need them most.

Our Expanded Focus Needing
Financial Support

While infectious diseases like HIV, TB, and hepatitis remain significant, non-communicable diseases such as cancer, diabetes,
and cardiovascular disease now account for more than 70% of deaths worldwide. MPP is expanding its efforts to include
patented essential medicines for NCDs, ensuring that these life-saving treatments are accessible to those in need.

While infectious diseases like HIV, TB, and hepatitis remain significant, non-communicable diseases such as cancer, diabetes,
and cardiovascular disease now account for more than 70% of deaths worldwide. MPP is expanding its efforts to include
patented essential medicines for NCDs, ensuring that these life-saving treatments are accessible to those in need.

While infectious diseases like HIV, TB, and hepatitis remain significant, non-communicable diseases such as cancer, diabetes,
and cardiovascular disease now account for more than 70% of deaths worldwide. MPP is expanding its efforts to include
patented essential medicines for NCDs, ensuring that these life-saving treatments are accessible to those in need.

While infectious diseases like HIV, TB, and hepatitis remain significant, non-communicable diseases such as cancer, diabetes,
and cardiovascular disease now account for more than 70% of deaths worldwide. MPP is expanding its efforts to include
patented essential medicines for NCDs, ensuring that these life-saving treatments are accessible to those in need.

Financial needs

At the moment, there is a significant gap to achieve our strategic goals and the secured financial coverage from grants.

Your support is crucial in helping us bridge this gap and continue our mission

MPP current funders in 2025

While MPP has expanded its donor base thanks to growing momentum, recent reductions in global health funding risk slowing
this progress. Additional support is urgently needed to sustain and scale this critical work.

Founder &
Funder since 2010

Funder since 2018

Funder since 2021

Funder since 2021

Funder since 2022

Funder since 2022

Funder since 2023

Funder since 2025

How you can help

Partner and Support

We are actively seeking financial support from a diverse range of organisations and countries. By partnering with MPP, you can help us scale our impact and contribute to a more resilient, equitable global health system. Your contributions will enable us to expand our reach and ensure that life-saving scientific advancements are accessible to those who need them the most. MPP is very small for what it achieves, saving the global health community billions of dollars.

Spread the Word

Help us raise awareness about the urgent need for access to affordable, qualityassured medicines in low- and middle-income countries. Share our mission with your network and encourage others to join us in making a difference.

Join us in making a difference. Together, we can achieve a more resilient, equitable global health system. Thank you for your support.

Contact Us

If you have any questions or would like to discuss how you can support our work, please reach
out to us. We would love to hear from you and explore ways we can collaborate.

For specific inquiries, please contact Vittorio at vgiorgetti@medicinespatentpool.org
For general information, email us at fundraising@medicinespatentpool.org

Address: Rue de Varembé 7, 1202 Geneva, Switzerland